Journal of Cancer Research and Clinical Oncology

, Volume 134, Issue 12, pp 1325–1335 | Cite as

A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma

  • Kimberly B. Higginbotham
  • Richard Lozano
  • Thomas Brown
  • Yehuda Z. Patt
  • Takashi Arima
  • James L. Abbruzzese
  • Melanie B. ThomasEmail author
Original Paper



Preclinical models showed TAC-101 (4-[3,5-bis(trimethylsilyl) benzamide] benzoic acid), an oral synthetic retinoid, has anti-tumor activity in hepatocellular carcinoma (HCC). A phase I/II study was performed in advanced HCC patients (pts).

Patients and methods

Thirty-three patients were enrolled. During Phase I, pts received 40 mg daily for 14 days q3 weeks; 2 of 5 patients developed DLT so dose was reduced to 20 mg/day. Twenty-eight patients received 20 mg/day.


No pt had a CR or PR, but 12 of 21 (57%) had SD. Two pts (9.5%) had late PR after discontinuing TAC-101. Median survival (MS) for all 28 pts treated with 20 mg/day was 12.7 months (95% CI 8.8–22.7); MS for 21 evaluable pts was 19.2 months (95% CI 10.4–27.6).


20 mg of TAC- was well tolerated. Significant disease stabilization (12/21 pts, 57%), 2 late PRs, and prolonged MS (19.2 months) suggest that TAC-101 provides meaningful patient benefit.


Hepatocellular carcinoma Clinical trial Retinoids TAC-101 Survival 


  1. Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26):4293–4300PubMedCrossRefGoogle Scholar
  2. Abrams RA, Pajak TF, Haulk TL, Flam M, Asbell SO (1998) Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. Cancer J Sci Am 4(3):178–184PubMedGoogle Scholar
  3. Barbare JC, Bouche O, Bonnetain F et al (2005) Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 23(19):4338–4346PubMedCrossRefGoogle Scholar
  4. Boige V, Taieb J, Hebbar M et al (2006) Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 42(4):456–459PubMedCrossRefGoogle Scholar
  5. Bruserud O, Gjertsen BT (2000) New strategies for the treatment of acute myelogenous leukemia: differentiation induction-present use and future possibilities. Stem Cells 18:157–165PubMedCrossRefGoogle Scholar
  6. Dimery IW, Hong WK, Lee JJ et al (1997) Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. Ann Oncol 8(1):85–89PubMedCrossRefGoogle Scholar
  7. Eferl R, Ricci R, Kenner L et al (2003) Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112(2):181–192PubMedCrossRefGoogle Scholar
  8. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139(10):817–823PubMedGoogle Scholar
  9. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340(310):745–750PubMedCrossRefGoogle Scholar
  10. Fuchs CS, Clark JW, Ryan DP et al (2002) A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 94(12):3186–3191PubMedCrossRefGoogle Scholar
  11. Fujimoto K, Hosotani R, Doi R et al (1999) Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. Int J Cancer 81(4):637–644PubMedCrossRefGoogle Scholar
  12. Gish RG, Porta C, Lazar L et al (2007) Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25(21):3069–3075PubMedCrossRefGoogle Scholar
  13. Guan Z, Wang Y, Maoleekoonpairoj S et al (2003) Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 89(10):1865–1869PubMedCrossRefGoogle Scholar
  14. Guo L, Guo Y, Xiao S, Shi X (2005) Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma. Life Sci 77(15):1869–1878PubMedCrossRefGoogle Scholar
  15. Hashimoto Y, Kagechika H, Kawachi E et al (1996) Evaluation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4. Biol Pharm Bull 19:1322–1328PubMedGoogle Scholar
  16. Hasumi A, Matsui H, Sugioka A et al (2000) Precancerous conditions of biliary tract cancer in patients with pancreaticobiliary maljunction: reappraisal of nationwide survey in Japan. J Hepatobiliary Pancreat Surg 7(6):551–555PubMedCrossRefGoogle Scholar
  17. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C (2005) A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 103(4):756–762PubMedCrossRefGoogle Scholar
  18. Kato H, Nakamura M, Muramatsu M, Orito E, Ueda R, Mizokami M (2004) Spontaneous regression of hepatocellular carcinoma: two case reports and a literature review. Hepatol Res 29(3):180–190PubMedCrossRefGoogle Scholar
  19. Kim WR, Brown RS Jr, Terrault NA, El-Serag H (2002) Burden of liver disease in the United States: summary of a workshop. Hepatology 36(1):227–242PubMedCrossRefGoogle Scholar
  20. Lee J, Park JO, Kim WS et al (2004) Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 54(5):385–390PubMedCrossRefGoogle Scholar
  21. Lee SJ, Ohashi Y, Sakurai H, Saiki I (2003) TAC-101 inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. Cancer Lett 198(2):169–177PubMedCrossRefGoogle Scholar
  22. Leung CS, Tang CN, Fung KH, Li MK (2002a) A retrospective review of transcatheter hepatic arterial embolisation for ruptured hepatocellular carcinoma. J R Coll Surg Edinb 47(5):685–688PubMedGoogle Scholar
  23. Leung TW, Tang AM, Zee B et al (2002b) Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 94(2):421–427PubMedCrossRefGoogle Scholar
  24. Lin F, Xiao D, Kolluri SK, Zhang X (2000) Unique anti-activator protein-1 activity of retinoic acid receptor beta. Cancer Res 60(12):3271–3280PubMedGoogle Scholar
  25. Lippman SM (1997) Head and neck chemoprevention: recent advances. Cancer Control 4(2):128–135PubMedGoogle Scholar
  26. Lippman SM, Benner SE, Hong WK (1993a) Chemoprevention strategies in lung carcinogenesis. Chest 103(1 Suppl):15S–19SPubMedCrossRefGoogle Scholar
  27. Lippman SM, Benner SE, Hong WK (1993b) Retinoids in chemoprevention of head and neck carcinogenesis. Prev Med 22(5):693–700PubMedCrossRefGoogle Scholar
  28. Lippman SM, Garewal H, Meyskens FL Jr (1989) Retinoids as potential chemopreventive agents in squamous cell carcinoma of the head and neck. Prev Med 18:740–48PubMedCrossRefGoogle Scholar
  29. Llovet JM, Bruix J (2000) Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 32(3):679–680PubMedCrossRefGoogle Scholar
  30. Llovet JM, Ricci S, Mazzaferro V et al (2007) Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebo-controlled trials (SHARP trial). American Society of Clinical Oncology Annual Meeting, ChicagoGoogle Scholar
  31. Lotan R (1997) Retinoids and chemoprevention of aerodigestive tract cancers. Cancer Metastasis Rev 16(3–4):349–356PubMedCrossRefGoogle Scholar
  32. Matsushima-Nishiwaki R, Okuno M, Takano Y, Kojima S, Friedman SL, Moriwaki H (2003) Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 24(8):1353–1359PubMedCrossRefGoogle Scholar
  33. Matthews CP, Colburn NH, Young MR (2007) AP-1 a target for cancer prevention. Curr Cancer Drug Targets 7(4):317–324PubMedCrossRefGoogle Scholar
  34. Mechta-Grigoriou F, Gerald D, Yaniv M (2001) The mammalian Jun proteins: redundancy and specificity. Oncogene 20(19):2378–2389PubMedCrossRefGoogle Scholar
  35. Meyskens FL Jr, Jacobson J, Nguyen B, Weiss GR, Gandara DR, MacDonald JS (1998) Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). Invest New Drugs 16(2):171–173PubMedCrossRefGoogle Scholar
  36. Minagawa N, Nakayama Y, Inoue Y et al (2004) 4-[3, 5-Bis(trimethylsilyl) benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor. Oncol Res 14(9):407–414PubMedGoogle Scholar
  37. Miyagawa N, Homma T, Kagechika H, Shudo K, Nagai H (2003) Effect of synthetic retinoid, TAC-101, on experimental autoimmune disease. Pharmacology 67(1):21–31PubMedCrossRefGoogle Scholar
  38. Miyaguchi T, Nomata K, Noguchi M et al (2001) TAC-101, a novel retinobenzoic-acid derivative, enhances gap junctional intercellular communication among renal epithelial cells treated with renal carcinogens. Anticancer Res 21:4025–4030PubMedGoogle Scholar
  39. Mok TS, Leung TW, Lee SD et al (1999) A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 44(4):307–311PubMedCrossRefGoogle Scholar
  40. Murakami K, Wierzba K, Sani M et al (1998a) TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span. Clin Exp Metastasis 16:323–331PubMedCrossRefGoogle Scholar
  41. Murakami K, Matsuura T, Sano M et al (1998b) 4-[3, 5-Bis(trimethylsilyl) benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals. Clin Exp Metastasis 16(7):633–643PubMedCrossRefGoogle Scholar
  42. Murakami K, Yamaura T, Suda K et al (1999) TAC-101 (4-[3, 5-bis(trimethylsilyl) benzamido]benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma. Jpn J Cancer Res 90(11):1254–1261PubMedGoogle Scholar
  43. Muto Y, Moriwaki H, Ninomiya M et al (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334(24):1561–1567PubMedCrossRefGoogle Scholar
  44. Muto Y, Moriwaki H, Saito A (1999) Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340(13):1046–1047PubMedCrossRefGoogle Scholar
  45. Ohtani H, Yamazaki O, Matsuyama M et al (2005) Spontaneous regression of hepatocellular carcinoma: report of a case. Surg Today 35(12):1081–1086PubMedCrossRefGoogle Scholar
  46. Oikawa T (1998) Control of tumor-related angiogenesis. Hum Cell 11:201–206PubMedGoogle Scholar
  47. Oikawa T, Murakami K, Sano M, Shibata J, Wierzba K, Yamada Y (2001) A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases of human stomach cancer cells. Jpn J Cancer Res 92(11):1225–1234PubMedGoogle Scholar
  48. Papadimitrakopoulou VA, Hong WK (1997) Retinoids in head and neck chemoprevention. Proc Soc Exp Biol Med 216(2):283–290PubMedGoogle Scholar
  49. Parkin DM, Pisani P, Ferlay J (1999a) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80(6):827–841PubMedCrossRefGoogle Scholar
  50. Parkin DM, Pisani P, Ferlay J (1999b) Global cancer statistics. CA Cancer J Clin 49(1):33–64PubMedCrossRefGoogle Scholar
  51. Patt YZ, Hassan MM, Lozano RD et al (2005) Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 103(4):749–755PubMedCrossRefGoogle Scholar
  52. Philip PA, Mahoney MR, Allmer C et al (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23(27):6657–6663PubMedCrossRefGoogle Scholar
  53. Posey J, Johnson P, Mok T, Hirmand M, Dahlberg S, Kwei L, Leung T (2005) Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin (DOX) in chemotherapy-naive, unresectable hepatocelular carcinoma (HC). 2005 ASCO Annual Meeting, Orlando, FL, USAGoogle Scholar
  54. Rizvi NA, Marshall JL, Ness E et al (2002) Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol 20(16):3522–3532PubMedCrossRefGoogle Scholar
  55. Sako T, Nakayama Y, Minagawa N et al (2005) 4-[3, 5-Bis(trimethylsily) benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression. In Vivo 19:125–132PubMedGoogle Scholar
  56. Sankaranarayanan, Mathew RB (1996) Retinoids as cancer-preventive agents. IARC Sci Publ (139):47–59Google Scholar
  57. Sano K, Takayama T, Murakami K, Saiki I, Makuuchi M (2003) Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma. Clin Cancer Res 9(10 Pt 1):3679–3683PubMedGoogle Scholar
  58. Satake K, Takagi E, Ishii A et al (2003) Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma. Auris Nasus Larynx 30(4):403–412PubMedCrossRefGoogle Scholar
  59. Shudo K, Kagechika H, Yamazaki N et al (2004) A synthetic retinoid Am80 (tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm. Biol Pharm Bull 27:1887–1889PubMedCrossRefGoogle Scholar
  60. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1–10PubMedCrossRefGoogle Scholar
  61. Suzuki N, Aoki D, Oie S et al (2004) A novel retinoid, 4-[3, 5-bis (trimethylsilyl) venzamido] benzoic acid (TAC-101), induces apoptosis of human ocarian carcinoma cells and shows potential as a new antitumor agent for clear cell adneocarcinoma. Gynecol Oncol 94:643–649PubMedCrossRefGoogle Scholar
  62. Takai K, Okuno M, Yasuda I et al (2005) Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology 48(1):39–45PubMedCrossRefGoogle Scholar
  63. Ventegodt S, Morad M, Hyam E, Merrick J (2004) Clinical holistic medicine: induction of spontaneous remission of cancer by recovery of the human character and the purpose of life (the life mission). Sci World J 4:362–377Google Scholar
  64. Wang ZY, Sun GL, Lu JX, Gu LJ, Huang ME, Chen SR (1990) Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China. Nouv Rev Fr Hematol 32(1):34–36PubMedGoogle Scholar
  65. Yasuda I, Shiratori Y, Adachi S et al (2002) Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 36(5):660–671PubMedCrossRefGoogle Scholar
  66. Yeo W, Mok TS, Zee B et al (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97(20):1532–1538PubMedCrossRefGoogle Scholar
  67. Yoshimura K, Uchida G, Okazaki M et al (2003) Differential expression of heparin-binding EGF-like growth factor (HB-EGF) mRNA in normal human keratinocytes induced by a variety of natural and synthetic retinoids. Exp Cell Res 12(S2):28–34Google Scholar
  68. Yuen MF, Wu PC, Lai VC, Lau JY, Lai CL (2001) Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer 91(1):106–112PubMedCrossRefGoogle Scholar
  69. Zhang JW, Wang JY, Chen SJ, Chen Z (2000) Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. J Biosci 25(3):275–284PubMedCrossRefGoogle Scholar
  70. Zhu AX, Blaszkowsky LS, Ryan DP et al (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(12):1898–1903PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Kimberly B. Higginbotham
    • 1
  • Richard Lozano
    • 1
  • Thomas Brown
    • 1
  • Yehuda Z. Patt
    • 2
  • Takashi Arima
    • 3
  • James L. Abbruzzese
    • 1
  • Melanie B. Thomas
    • 1
    Email author
  1. 1.Department of Gastrointestinal Medical Oncology Unit 426The University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.University of New Mexico Cancer Research and Treatment CenterAlbuquerqueUSA
  3. 3.Taiho Pharmaceutical Co., LtdTokyoJapan

Personalised recommendations